• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

    To view the announcements please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Board of Directors

David Flacks
Chairman

David has a number of governance roles and is also a corporate lawyer with boutique corporate law firm Flacks & Wong. David is chair of the NZX Regulatory Governance Committee, Harmoney Corp and biotech start up Upside Biotechnologies, and is a director of the Suncorp NZ group of companies and NZ Venture Investment Fund. David was previously chair of the NZX Markets Disciplinary Tribunal and was a member of the Takeovers Panel. He also holds a number of pro bono directorships. David was for many years a senior corporate partner at Bell Gully and was general counsel and company secretary of Carter Holt Harvey during the 1990’s. He is a law graduate from Cambridge University.

Close
David Flacks
Chairman
View More
Dr. Hartley Atkinson

Hartley has a Masters of Pharmaceutical Chemistry with Distinction (1983) and Doctorate in Pharmacology from Otago University (1989). He published 17 research papers and 2 book chapters prior to entering industry. Before establishing AFT Pharmaceuticals, Hartley had 8 years in multinational pharmaceutical companies in various positions including Medical Director and Sales and Marketing Director.

Close
Dr. Hartley Atkinson
View More
Marree Atkinson

Prior to co-founding AFT Pharmaceuticals, Marree was a registered nurse at Waikato Hospital. She also worked with Air New Zealand. Marree has been a central figure in building the company since its inception. She has directed developments across key parts of the business, including financial control, regulatory/compliance, brand awareness, international market growth and human resources. She is the company’s Chief of Staff overseeing staff, commercial contracts, and special projects.

Close
Marree Atkinson
View More
Doug Wilson

Doug Wilson was a New Zealand physician and academic. He joined a major International pharmaceutical company, Boehringer Ingelheim, working in their US subsidiary, becoming their Head of Medical Research and Regulatory Affairs, the interface with FDA, playing a major role in steering 10 drugs through the FDA to the US and global markets. He moved to Head Office in Germany, being responsible for those same functions for worldwide drug development. He chaired the company’s International Medical Committee overseeing the medical aspects of all drugs in development globally, and their Internal Labeling Committee for the drugs on the worldwide market. He was the medical parent of Spiriva, a drug for Chronic Obstructive Pulmonary Disease (COPD) one of the major global killers. The drug last year sold $5 billion. He now consults internationally on new drugs in development, and for pharmaceutical companies.

Close
Doug Wilson
View More
Jon Lamb

Jon has lead strategic planning, marketing and restructuring of companies throughout his career. He worked in and headed a multinational pharmaceutical company successfully launching global brands. He created the kiwifruit brand Zespri, and restructured the company into a retail focused operation. He has been a board director on a number of public and private companies, for example a recent a start-up that was developing an antiviral against AIDS where he worked closely with Harvard Medical School who sponsored the clinical trials. He was Deputy Chair of an Australian diagnostic company that had a real time tool for measuring the Hepatitis B virus. He has been involved with AFT Pharmaceuticals Ltd since 2004. He is a member of the Institute of Directors.

Close
Jon Lamb
View More
Nathan Hukill

Nate Hukill is the President and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of investing experience. Prior to joining CRG, Mr. Hukill was a Portfolio Manager at Highland Capital, where he invested and managed approximately $4.5 billion in the healthcare, consumer products, and technology sectors. Before Highland Capital, Mr. Hukill co-founded a pharmaceutical-focused enterprise software company called OpenQ, Inc. He started his career as a credit investor at Salomon Smith Barney where he managed a portfolio of approximately $800 million.

Close
Nathan Hukill
View More
Jim Burns

Jim is Chairman of Assurex Health, and from 2009-2015 served as Executive Chairman and Chief Executive Officer. Previous roles include President of MedPointe Pharmaceuticals, President & CEO of Osiris Therapeutics, General Partner of Healthcare Ventures and Group President of Becton Dickinson.

Close
Jim Burns
View More